Firazyr

  • Email
  • Help

Questions & Answers

On 14 September 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Firazyr. The marketing authorisation holder for this medicinal product is Shire Orphan Therapies GmbH.

The CHMP adopted an extension to the existing indication as follows:1

“Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older,(with C1-esterase-inhibitor deficiency).”

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. 


1 New text in bold, removed text as strikethrough

Name Language First published Last updated
CHMP post-authorisation summary of positive opinion for Firazyr (II-34-G) (English only) 2017-09-15  

Key facts

Product details for Firazyr
NameFirazyr
INN or common name

icatibant

Therapeutic area Angioedemas, Hereditary
Active substance

icatibant

Date opinion adopted14/09/2017
Company name

Shire Orphan Therapies GmbH

StatusPositive
Application typePost authorisation